# Rgenta Therapeutics, Inc.: Form D capital raise (Woburn, MA)

**Vendor Spend Propensity Score (CPA / Tax / Audit):** 83/100
**Estimated post-raise budget for this service type:** $837,046 (heuristic)

| Field | Value |
|---|---|
| Industry | Other Technology (Technology & SaaS) |
| Operating company | Yes |
| Exemption | 506(b) |
| Amount sold | $41,852,307 |
| Total offering | $130,107,279 |
| Investors so far | 9 |
| First sale | 2026-10-19 |
| Filed | 2026-11-03 |
| Entity | Corporation |

## Executives and related persons (as listed in the filing)
- Hualin Simon Xi: Executive Officer, Director
- Yichao Fan: Director
- Debasish Roychowdhury: Director
- Julia Kaufman: Director
- Sean Zhang: Director, Promoter
- Cillian King: Director, Promoter
- James Kasuboski: Director
- Travis Wager: Executive Officer
- Weng Zhiping: Director
- Jeff Guckert: Executive Officer

## Why this score
- Operating company: new capital typically funds hiring, facilities and vendors.
- Raised $41,852,307 so far: a large raise.
- Technology & SaaS companies are a strong fit for CPA / Tax / Audit services.
- New filing (not an amendment): the raise is fresh.
- Filed 2 days ago.

Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) (https://www.sec.gov/Archives/edgar/data/1801266/000123191926001529/). Last refreshed: 2026-11-04T09:16:10.755Z.
Informational only. SEC EDGAR Form D data is shown for business-development research; it is not investment advice and not an offer or solicitation to buy or sell any security. Not legal or financial advice.